, a specialty pharmaceutical company centered on bringing proprietary medications to the China market. Jian An is definitely headquartered in Shenzhen, China and has a 25-year history of offering pharmaceutical and additional medical items in the China marketplace. This new application is expected to provide additional IP protection along with the potential for a fresh indication for MuGard. Related StoriesNew results reveal association between colorectal tumor and melanoma drug treatmentNew RNA check of blood platelets may be used to detect area of cancerViralytics enters into medical trial collaboration contract with MSD We are excited about the new romantic relationship with Jian An in China, since it greatly expands our reach throughout the region with significant product sales representative presence, said Sven de Backer, CFO of RHEI Pharmaceuticals.As expected, age and IPSS risk group were strongly associated with overall survival . But mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 also emerged as independent predictors of survival. Mutation of NRAS, reported as a marker of poor prognosis previously, did not influence survival in this model, most likely due to strong associations among oncogenic NRAS components and mutations of the IPSS. EZH2 mutations, which have not been associated with known prognostic markers previously, retained a solid association with survival in our model. This analysis signifies that evaluation of the mutation status of TP53, EZH2, ETV6, RUNX1, and ASXL1 would add the the majority of information to clinical prognostic scores as presently assessed in sufferers with myelodysplastic syndromes.